Get started
Author

David Gleeson

Observed names: D Gleeson, D. Gleeson, Gleeson, David
Observed institutions: Guy's Hospital, King's College London, Guy's and St Thomas' NHS Foundation Trust, East Surrey Hospital, Charing Cross Hospital, Surrey and Sussex Healthcare NHS Trust, Imperial College London
ORCID: 0000-0002-7355-9281
Observed ORCID: 0000-0002-7355-9281
OpenAlex ID: A5004695280
Medical Student Schwartz Rounds: A Powerful Medium for Medical Student Reflective Practice
2020 · David Gleeson, James Arwyn-Jones, et al. · Advances in Medical Education and Practice · 24
PDF
Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic
2022 · David Gleeson, Jonathan N W N Barker, et al. · British Journal of Dermatology · 20
PDF
Eruptive keratoacanthomas associated with dupilumab therapy
2021 · D. Gleeson, S. Cliff, et al. · British Journal of Dermatology · 9
Remission of Chronic Actinic Dermatitis on Baricitinib: A Case Report
2023 · Jessica Maguire, David Gleeson, et al. · Skin Health and Disease · 8
PDF
Acceptability of ‘as needed’ biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study
2024 · David Gleeson, Maneeha Naveed, et al. · British Journal of Dermatology · 6
Prevalence of comorbidity amongst people with palmoplantar pustulosis: A systematic review and meta‐analysis
2025 · David Gleeson, Mark Corbett, et al. · Journal of the European Academy of Dermatology and Venereology · 3
Imsidolimab: an emerging biological therapy for generalized pustular psoriasis
2023 · David Gleeson, Satveer K Mahil · British Journal of Dermatology · 3
Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol
2025 · David Gleeson, Sarah Chapman, et al. · BMJ Open · 2
Bacterial skin infections
2019 · David Gleeson · InnovAiT Education and inspiration for general practice · 1
Upadacitinib for Palmoplantar Pustulosis: An Open-label, Assessor-blinded Feasibility Study Using Historic Control Data (JAKPPPOT)
2026 · David Gleeson, Sarah Chapman, et al. · British Journal of Dermatology
Can Systemic Immunomodulatory Therapy Induce Remission of Atopic Dermatitis? A Systematic Review
2026 · David Gleeson, John Y. W. Lee, et al. · Journal of Cutaneous Medicine and Surgery
P141 Maintaining disease control on systemic immunomodulatory therapy for psoriasis: a systematic review and meta-analysis
2026 · Weiyu Ye, Mark Corbett, et al. · British Journal of Dermatology
120 Maximising clinical trial outputs: a UK experience implementing efficiency innovations
2025 · D Gleeson, C Smith, et al. · Journal of Investigative Dermatology
PDF
P142 Acceptability and experiences of multiple skin biopsies in atopic dermatitis: a longitudinal cohort study
2025 · Bindi Gaglani, David Gleeson, et al. · British Journal of Dermatology
PDF
P101 Janus kinase inhibitors in palmoplantar pustulosis: a systematic review and meta-analysis of comorbidity burden to inform a feasibility trial’s design (JAKPPPOT)
2025 · David Gleeson, Mark Corbett, et al. · British Journal of Dermatology
PDF
104 Prevalence of comorbidities amongst people with palmoplantar pustulosis: a systematic review and meta-analysis
2024 · D. Gleeson, S. Choy, et al. · Journal of Investigative Dermatology
PDF
An assessment of the acceptability and practicality of using Janus kinase inhibitors to treat palmoplantar pustulosis
2024 · David Gleeson, Catherine Smith · http://isrctn.com/
P91 Exploring acceptability of ‘as required’ biologic therapy in psoriasis remission: insights from multistakeholder focus groups
2023 · Maneeha Naveed, Satveer Mahil, et al. · British Journal of Dermatology
PDF
Are Janus kinase inhibitors an effective treatment for palmoplantar pustulosis? A critically appraised topic.
2022 · Gleeson, David · Figshare
Works count: 21
Citation count: 76
H-index: 5
I10-index: 2
Year
Topic
Type